Friday's ETF Winners & Losers

HealthShares Emerging Cancer is up 11% on Dendreon's good news.
Author:
Publish date:

The

HealthShares Emerging Cancer

(HHJ)

exchange-traded fund was Friday's best performer.

Dendreon

(DNDN)

soared 164.2% after the Food and Drug Administration said the company's prostate cancer vaccine treatment, Provenge, was safe and effective in treating prostate cancer. The ETF was jumping $2.40, or 10.7%, to $24.82.

Other biotech and health care ETFs were gaining ground. The

PowerShares FTSE RAFI Health Care

(PRFH)

was adding 4% to $50.98. The

First Trust Amex Biotechnology Index

(FBT) - Get Report

was gaining 1% to $23.84. The

SPDR S&P Biotech

(XBI) - Get Report

was up 0.9% at $48.22.

On the other hand, the

B2B Internet HOLDRs

(BHH)

ETF was lower, as holdings

Ariba

(ARBA)

and

Checkfree

(CKFR)

were shedding 1.5%. The ETF was off 4 cents, or 1.8%, to $2.14.

Bundled securities tracking the energy sector were also among the losers of the day, as oil prices retraced some of its 6% gain for the week. The front-month May crude contract was recently losing 26 cents to $65.77 a barrel.

The

Energy Select Sector SPDR

(XLE) - Get Report

ETF was recently down 1.4% to $60.25. The

iShares Dow Jones U.S. Oil Equipment Index

(IEZ) - Get Report

ETF was off 1.3% to $48.14. The

PowerShares Dynamic Energy Exploration

(PXE) - Get Report

ETF was losing 1.2% to $20.30. The

Oil Services HOLDRs

(OIH) - Get Report

ETF eased 1.1% to $146.35.